- Diet
- Cancer
- Colorectal Cancer
- Prostate Cancer
- Breast Cancer
- Adenoid Cystic Carcinoma
- Amyloidosis
- Anal Cancer
- Appendix Cancer
- Astrocytoma - Childhood
- Ataxia-Telangiectasia
- Beckwith-Wiedemann Syndrome
- Bile Duct Cancer (Cholangiocarcinoma)
- Birt-Hogg-Dubé Syndrome
- Bladder Cancer
- Bone Cancer (Sarcoma of Bone)
- Brain Stem Glioma - Childhood
- Brain Tumor
- Breast Cancer - Inflammatory
- Breast Cancer - Metastatic
- Breast Cancer - Male
- Carney Complex
- Central Nervous System Tumors (Brain and Spinal Cord) - Childhood
- Cervical Cancer
- Childhood Cancer
- Cowden Syndrome
- Craniopharyngioma - Childhood
- Desmoid Tumor
- Desmoplastic Infantile Ganglioglioma, Childhood Tumor
- Ependymoma - Childhood
- Esophageal Cancer
- Ewing Sarcoma - Childhood and Adolescence
- Eye Melanoma
- Eyelid Cancer
- Familial Adenomatous Polyposis
- Familial GIST
- Familial Malignant Melanoma
- Familial Pancreatic Cancer
- Gallbladder Cancer
- Gastrointestinal Stromal Tumor - GIST
- Germ Cell Tumor - Childhood
- Gestational Trophoblastic Disease
- Head and Neck Cancer
- Hereditary Breast and Ovarian Cancer
- Hereditary Diffuse Gastric Cancer
- Hereditary Leiomyomatosis and Renal Cell Cancer
- Hereditary Mixed Polyposis Syndrome
- Hereditary Pancreatitis
- Hereditary Papillary Renal Carcinoma
- HIV/AIDS-Related Cancer
- Juvenile Polyposis Syndrome
- Kidney Cancer
- Laryngeal and Hypopharyngeal Cancer
- Leukemia - Acute Lymphoblastic - ALL - Childhood
- Leukemia - Acute Lymphocytic - ALL
- Leukemia - Acute Myeloid - AML
- Leukemia - Acute Myeloid - AML - Childhood
- Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia
- Leukemia - Chronic Lymphocytic - CLL
- Leukemia - Chronic Myeloid - CML
- Leukemia - Chronic T-Cell Lymphocytic
- Leukemia - Eosinophilic
- Li-Fraumeni Syndrome
- Liver Cancer
- Lung Cancer - Non-Small Cell
- Lung Cancer - Small Cell
- Lymphoma - Hodgkin
- Lymphoma - Hodgkin - Childhood
- Lynch Syndrome
- Lymphoma - Non-Hodgkin - Childhood
- Lymphoma - Non-Hodgkin
- Mastocytosis
- Medulloblastoma - Childhood
- Melanoma
- Meningioma
- Mesothelioma
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type 2
- Multiple Myeloma
- MUTYH (or MYH)-Associated Polyposis
- Myelodysplastic Syndromes - MDS
- Nasal Cavity and Paranasal Sinus Cancer
- Nasopharyngeal Cancer
- Neuroblastoma - Childhood
- Neuroendocrine Tumor of the Gastrointestinal Tract
- Neuroendocrine Tumor of the Lung
- Neuroendocrine Tumor of the Pancreas
- Neuroendocrine Tumors
- Neurofibromatosis Type 1
- Neurofibromatosis Type 2
- Nevoid Basal Cell Carcinoma Syndrome
- Oral and Oropharyngeal Cancer
- Osteosarcoma - Childhood and Adolescence
- Ovarian, Fallopian Tube, and Peritoneal Cancer
- Pancreatic Cancer
- Parathyroid Cancer
- Penile Cancer
- Peutz-Jeghers Syndrome
- Pheochromocytoma and Paraganglioma
- Pituitary Gland Tumor
- Pleuropulmonary Blastoma - Childhood
- Retinoblastoma - Childhood
- Rhabdomyosarcoma - Childhood
- Salivary Gland Cancer
- Sarcoma - Kaposi
- Sarcomas, Soft Tissue
- Skin Cancer (Non-Melanoma)
- Small Bowel Cancer
- Stomach Cancer
- Testicular Cancer
- Thymoma and Thymic Carcinoma
- Thyroid Cancer
- Tuberous Sclerosis Complex
- Unknown Primary
- Uterine Cancer
- Vaginal Cancer
- Von Hippel-Lindau Syndrome
- Vulvar Cancer
- Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
- Werner Syndrome
- Wilms Tumor - Childhood
- Xeroderma Pigmentosum
- Veterans with Cancer
- Insurance and Cancer
- Prayers for Cancer Healing
- Prayers for Cancer Survival
- Pharmacology - Cancer Oncology drugs
- Natural Cures for Cancer
- Cancer Causing Foods
- Cancer Fighting Foods
- Kaposi Sarcoma
- Nausea and Vomiting in Cancer
- Adrenocortical Carcinoma
- Adolescents and Young Adults with Cancer
- Basal Cell Carcinoma of the Skin
- Burkitt Lymphoma
- Pancreatic Cancer
- Pain Management in Cancer
- CBD and Cancer Patients
- Cancer Treatment
- Stoma Bag
- Cancer Bra
- Cancer Wigs
- Lymphedema and Cancer
- Ductal Carcinoma In Situ (DCIS)
- Mouth Cancer
- Pregnancy and Breast Cancer
- Endometrial Cancer
- Heart Tumors, Childhood
- Merkel Cell Carcinoma
- Urethral Cancer
- Cancer in Young Adults
- Exercise and Cancer
- Insurance Denial and Cancer
- Bronchial Tumors
- Colostomy and Cancer
- Tube Feeding and Cancer
- Chronic Myeloproliferative Neoplasms
- Pulmonary Inflammatory Myofibroblastic Tumor
- Cutaneous T-Cell Lymphoma
- Fallopian Tube Cancer
- Breast Prostheses after Mastectomy
- Vascular Tumors
- Urethral cancer
- Music
Up next
enteral nutrition, feeding tube, head and neck cancer, intensity-modulated radiotherapy (IMRT), tox
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
https://plus.google.com/commun....ities/11546213005465
,
,https://plus.google.com/u/0/+A....lexandrosGSfakianaki
,
https://www.youtube.com/channe....l/UCQH21WX8Qn5YSTKrl
,
https://www.youtube.com/channe....l/UCTREJHxB6yt4Gaqs4
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,
Pretreatment risk stratification of feeding tube use in patients treated with intensity-modulated radiotherapy for head and neck cancer.
Science.gov (United States)
Anderson, Nigel J; Jackson, James E; Smith, Jennifer G; Wada, Morikatsu; Schneider, Michal; Poulsen, Michael; Rolfo, Maureen; Fahandej, Maziar; Gan, Hui; Joon, Daryl Lim; Khoo, Vincent
2018-05-13 PubMed
DOI: 10.1002/hed.25316 ISSN: 1043-3074
Keywords: enteral nutrition, feeding tube, head and neck cancer, intensity-modulated radiotherapy (IMRT), toxicity
The purpose of this study was to establish a risk stratification model for feeding tube use in patients who undergo intensity-modulated radiotherapy (IMRT) for head and neck cancers. One hundred thirty-nine patients treated with definitive IMRT (+/- concurrent chemotherapy) for head and neck mucosal cancers were included in this study. Patients were recommended a prophylactic feeding tube and followed up by a dietician for at least 8 weeks postradiotherapy (post-RT). Potential prognostic factors were analyzed for risk and duration of feeding tube use for at least 25% of dietary requirements. Many variables had significant effects on risk and/or duration of feeding tube use in univariate analyses. Subsequent multivariable analysis showed that T classification ≥3 and level 2 lymphadenopathy were the best independent significant predictors of higher risk and duration of feeding tube use, respectively, in oral cavity, pharyngeal, and supraglottic primaries. In patients treated with definitive IMRT, T classification ≥3 and level 2 lymphadenopathy can potentially stratify patients into 4 risk groups for developing severe dysphagia requiring feeding tube use. © 2018 Wiley Periodicals, Inc.
SORT BY-
Top Comments
-
Latest comments